Effects of clacitonin epidural injection in patients with spinal canal stenosis

Evaluation the effects of clacitonin epidural injection in patients with degenerative spinal canal stenosis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120814010599N24

Enrollment

Registered

2019-03-01

Start date

2019-02-19

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

degenerative spinal canal stenosis. Spinal stenosis

Interventions

Intervention 1: Intervention group: Epidural caudal injection of 8 cc ropivacaine 0.2% (Product of @Sandoz company in German) with 50 units calcitonin (Product of @Rotexmedica company in France). The

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Unresponsive to usual low back pain treatments American society of Anesthesiologists class 1,2

Exclusion criteria

Exclusion criteria: Diabetes Anxiety or depression disorder coagulopathy or bleeding tendency addiction drug allergy local infection on the site of injection or systemic infection Patient dissatisfaction History of spinal surgery traumatic causes Congenital spinal cord defect Progressive neurological defect

Design outcomes

Primary

Measure	Time frame
Pain score and function before and after injection. Timepoint: before injection, 4, 8 and 12 weeks after. Method of measurement: OSWESTRY Disability Index ( ODI index ) and Numeric Rating scale ( NRS ).	—

Secondary

Measure	Time frame
Evaluation the quality of life. Timepoint: Before injection, 4, 8 and 12 weeks later. Method of measurement: ODI index( OSWESTRY Disability Index).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPoupak Rahimzadeh

Iran University of Medical Sciences

p-rahimzadeh@tums.ac.ir+98 21 6435 2326

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026